Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(15 sites)
Japan
Nagoya University Hospital, Nagoya, Aichi-ken National Cancer Center Hospital East, Kashiwa, Chiba Kurume University Hospital, Kurume, Fukuoka Hyogo Medical University Hospital, Nishinomiya, Hyōgo Kitasato University Hospital, Sagamihara, Kanagawa Kanagawa Cancer Center, Yokohama, Kanagawa Kochi Medical School Hospital, Nankoku, Kochi Kyoto University Hospital, Kyoto, Kyoto Kansai Medical University Hospital, Hirakata, Osaka Osaka International Cancer Institute, Osaka, Osaka Kindai University Hospital, Sakai, Osaka Saitama Medical University International Medical Center, Hidaka, Saitama Saitama Cancer Center, Shinden, Saitama Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital, Bunkyō-Ku, Tokyo The Cancer Institute Hospital Of JFCR, Koto-Ku, Tokyo